Second-line treatments improve HRQoL in pediatric ITP | ASH

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway 

  • All second-line treatments appear to significantly improve health-related quality of life (HRQoL) in pediatric immune thrombocytopenia (ITP), with rituximab having the greatest impact in decreasing fatigue at 1 month.

Why this matters 

  • Future analysis will consider the i...